8-K: uniQure Q3 2025: FDA Setback for AMT-130 Amidst Positive Data

uniQure reported Q3 2025 financial results, positive AMT-130 Huntington's data, but faces unexpected FDA feedback delaying BLA submission.

Summary

• Pivotal topline data from the Phase I/II study of AMT-130 in Huntington's disease met its primary and key secondary endpoints, demonstrating a statistically significant 75% slowing of disease progression measured by cUHDRS (p=.003) and a 60% slowing in Total Functional Capacity (TFC, p=0.033) at 36 months.
• A mean reduction from baseline in cerebrospinal neurofilament light protein (NfL) of -8.2% was observed at 36 months in the high-dose AMT-130 group.
• AMT-130 was generally well-tolerated with a manageable safety profile, with no new drug-related serious adverse events observed since December 2022.
• Preliminary feedback from the FDA at a pre-Biologics License Application (BLA) meeting for AMT-130 indicated a key shift, with the FDA currently no longer agreeing that data from the Phase I/II studies in comparison to an external control may be adequate to provide primary evidence for a BLA submission.
• The timing of the AMT-130 BLA submission remains unclear, and uniQure plans to urgently interact with the FDA to define next steps.
• Enrollment of the first three patients in the first cohort of the Phase I/IIa study of AMT-260 in mesial temporal lobe epilepsy was completed, with additional clinical data expected in the first half of 2026.
• Initial data from the Phase I/IIa study of AMT-191 in Fabry disease showed between 27to 208-fold increases in α-Gal A enzyme activity, with additional clinical data expected in the first half of 2026.
• Enrollment in the AMT-162 study for SOD1 amyotrophic lateral sclerosis (ALS) was voluntarily paused following an IDMC recommendation due to a dose-limiting toxicity and serious adverse event observed in one patient.
• The company raised approximately $323.7 million in net proceeds from an upsized public follow-on offering.
• Cash, cash equivalents, and current investment securities totaled $694.2 million as of September 30, 2025, up from $367.5 million as of December 31, 2024.
• The company refinanced its existing $50 million debt, extending the term to October 2030 and reducing its cost of capital, with options for additional term loan tranches.
• The company expects its cash, cash equivalents, and investment securities to be sufficient to fund operations into 2029.
• Revenue for the three months ended September 30, 2025, was $3.7 million, compared to $2.3 million in the same period in 2024.
• Research and development expenses increased to $34.4 million in Q3 2025 from $30.6 million in Q3 2024, partly due to BLA preparation for AMT-130.
• Selling, general and administrative expenses increased to $19.4 million in Q3 2025 from $11.6 million in Q3 2024, partly due to preparation for potential commercialization of AMT-130.
• The net loss for Q3 2025 was $80.5 million, or $1.38 basic and diluted loss per ordinary share, compared to a $44.4 million net loss, or $0.91 per share, in Q3 2024.

Sentiment

Score: 4

Explanation: While positive clinical data for AMT-130 and a strengthened cash position are favorable, the unexpected and significant regulatory setback with the FDA for AMT-130's BLA submission introduces substantial uncertainty and delays, overshadowing other positive developments. The pause in the AMT-162 study is also a negative.

Positives

• AMT-130 pivotal Phase I/II study met primary and key secondary endpoints, demonstrating statistically significant slowing of Huntington's disease progression (75% cUHDRS, 60% TFC) at 36 months.
• AMT-130 showed a manageable safety profile with no new drug-related serious adverse events observed since December 2022.
• Successfully completed an upsized public offering, raising approximately $323.7 million in net proceeds.
• Cash, cash equivalents, and investment securities increased to $694.2 million as of September 30, 2025, extending the cash runway into 2029.
• Refinanced $50 million debt, extending the term to October 2030 and reducing the cost of capital.
• Positive initial data from AMT-191 in Fabry disease, showing significant increases in α-Gal A activity (27to 208-fold).
• Advanced enrollment of the Phase I/IIa study of AMT-260 in mesial temporal lobe epilepsy.

Negatives

• Unexpected shift in FDA feedback regarding AMT-130 BLA submission, indicating Phase I/II data with external control may no longer be considered adequate primary evidence.
• Uncertainty in the timing of the AMT-130 BLA submission.
• Voluntary pause in enrollment for the AMT-162 study due to a dose-limiting toxicity and serious adverse event observed in one patient.
• Increased net loss to $80.5 million in Q3 2025 from $44.4 million in Q3 2024.
• Significant increase in non-operating items, net, primarily due to unfavorable foreign currency movements and a $5.7 million loss from changes in the fair value of pre-funded warrants liability.
• Income tax expense of $8.6 million in Q3 2025 compared to a benefit in Q3 2024, related to a 2023 royalty financing transaction.

Risks

• Clinical results may be unable to demonstrate data sufficient to support further clinical development or regulatory approval in any country where approval is pursued.
• More patient data becoming available could result in a different interpretation than the one derived from preliminary, interim, or topline data.
• Interactions with regulatory authorities, including the FDA, may affect the initiation, timing, and progress of clinical trials and pathways and timing for regulatory approval.
• Whether the measurements being evaluated are viewed as robust and sensitive measurements of disease progression suitable for regulatory approval.
• The company's ability to conduct and fund a Phase III or confirmatory study for AMT-130.
• The company's ability to continue to build and maintain the company infrastructure and personnel needed to achieve its goals.
• The company's effectiveness in managing current and future clinical trials and regulatory processes.
• The continued development and acceptance of gene therapies.
• The company's ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials.
• The company's ability to obtain, maintain, and protect intellectual property.
• The company's ability to fund its operations.

Future Outlook

The company expects its cash, cash equivalents, and investment securities to be sufficient to fund operations into 2029. It plans to urgently interact with the FDA to determine the most expeditious path forward for AMT-130's BLA submission. Additional clinical data for AMT-260 and AMT-191 are expected in the first half of 2026, and dosing for a fourth AMT-130 cohort is expected to complete before year-end 2025.

Management Comments

• "The third quarter of 2025 marked a defining moment for uniQure as we presented our topline three-year data of AMT-130, an investigational gene therapy for Huntington's disease, that demonstrated statistically significant slowing of disease progression." Matt Kapusta, CEO.
• "While the recent FDA feedback was unexpected and has introduced uncertainty in the timing of our BLA submission, we strongly believe that AMT-130 has the potential to bring substantial benefit for patients with Huntington's disease." Matt Kapusta, CEO.
• "We are fully committed to working with the FDA to determine the most expeditious path forward to rapidly bring AMT-130 to patients and their families in the U.S." Matt Kapusta, CEO.

Industry Context

The gene therapy sector continues to demonstrate significant potential for transformative treatments in severe diseases, as evidenced by uniQure's positive AMT-130 data in Huntington's disease. However, the unexpected regulatory feedback from the FDA highlights the inherent complexities and evolving standards in bringing novel gene therapies to market, which can significantly impact development timelines and investor sentiment. The pause in the AMT-162 study also underscores the high-risk nature of early-stage clinical development in this innovative field.

Stakeholder Impact

• Shareholders face significant uncertainty regarding the timeline and path to market for AMT-130, a key pipeline asset, which could negatively impact share price. However, the strengthened cash position provides financial stability.
• Patients with Huntington's disease may experience potential delays in accessing a promising therapy (AMT-130) due to regulatory hurdles, despite positive clinical data.
• Patients with SOD1 ALS are impacted by the enrollment pause in the AMT-162 study due to safety concerns, affecting potential treatment options.
• Employees will continue to focus on pipeline development and regulatory interactions, with potential strategic shifts based on FDA feedback.

Next Steps

• Urgently interact with the FDA to determine the most expeditious path forward for AMT-130's BLA submission.
• Complete patient dosing for the fourth cohort of high-dose AMT-130 before year-end 2025.
• Provide updated data from the AMT-260 study in the first half of 2026.
• Present updated results from the AMT-191 Phase I/IIa clinical trial in the first half of 2026.
• Continue to collect and evaluate data from the five patients treated in the AMT-162 EPISOD1 study.
• Attend Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025.
• Attend Stifel 2025 Healthcare Conference on November 13, 2025.

Key Dates

Recommendation

The positive clinical data for AMT-130 in Huntington's disease is a strong scientific validation, but the unexpected FDA feedback introduces significant regulatory risk and uncertainty regarding market entry timelines. While the company has a strong cash position and other pipeline assets, the primary value driver (AMT-130) faces a material setback. Investors should hold to await clarity on the FDA's requirements and the company's revised regulatory strategy before making further investment decisions.

Keywords

uniQure, QURE, gene therapy, Huntington's disease, AMT-130, FDA, BLA submission, clinical trials, financial results, cash runway, Fabry disease, AMT-191, epilepsy, AMT-260, ALS, AMT-162, biotech, pharmaceutical, Q3 2025